Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial

A novel cancer vaccine consisting of 20 mixed peptides (KRM-20) was designed to induce cytotoxic T lymphocytes (CTL) against twelve different tumor-associated antigens. The aim of this phase II trial was to examine whether KRM-20 in combination with docetaxel and dexamethasone enhances the antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Masanori, Arai, Gaku, Egawa, Shin, Ohyama, Chikara, Naito, Seiji, Matsumoto, Kazumasa, Uemura, Hirotsugu, Nakagawa, Masayuki, Nasu, Yasutomo, Eto, Masatoshi, Suekane, Shigetaka, Sasada, Tetsuro, Shichijo, Shigeki, Yamada, Akira, Kakuma, Tatsuyuki, Itoh, Kyogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183507/
https://www.ncbi.nlm.nih.gov/pubmed/32025848
http://dx.doi.org/10.1007/s00262-020-02498-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183507/
https://www.ncbi.nlm.nih.gov/pubmed/32025848
http://dx.doi.org/10.1007/s00262-020-02498-8

Ejemplares similares